Immunotherapy Combined with Chemotherapy as a Promising Therapy for a EGFR Exon 19 Deletion with MET Amplification Patient with Non-Small-Cell Lung Cancer: A Case Report

Advanced non-small-cell lung cancer (NSCLC) patients with EGFR exon 19 deletion often get benefits from the treatment of tyrosine kinase inhibitors (TKI). In the same way, the NSCLC patients with mesenchymal-to-epithelial transition (MET) amplification get benefits from crizotinib. The treatment bec...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, QingTao, Pan, Chi, Dai, ShengBin, Wang, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154000/
https://www.ncbi.nlm.nih.gov/pubmed/32308434
http://dx.doi.org/10.2147/OTT.S243988

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154000/
https://www.ncbi.nlm.nih.gov/pubmed/32308434
http://dx.doi.org/10.2147/OTT.S243988

Ejemplares similares